Online inquiry

IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12902MR)

This product GTTS-WQ12902MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FZD10 gene. The antibody can be applied in Synovial sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_007197.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 11211
UniProt ID Q9ULW2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12902MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9378MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ7902MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ1941MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ1287MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ15340MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ1074MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ8891MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW